Here are relevant reports on : cancer-immunotherapy-market
-
Viral Vector & Plasmid DNA Manufacturing Market by Type (Viral Vector (Retroviruses, Adenoviruses, AAV, Lentiviruses), Plasmid DNA), Workflow (Upstream, Downstream), Application (Cell & Gene Therapy), Diseases (Cancer), End User - Global Forecast to 2028
The global viral vector manufacturing market, valued at US$4.8 billion in 2022, stood at US$5.5 billion in 2023 and is projected to advance at a resilient CAGR of 18.2% from 2023 to 2028, culminating in a forecasted valuation of US$12.8 billion by the end of the period. The growth of this market is majorly driven by g rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, and effectiveness of viral vectors in gene therapy delivery.
- Published: June 2023
- Price: $ 4950
- TOC Available:
-
Asia Pacific Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)- Forecast to 2030
The Asia Pacific biomarkers Market, valued at US$13.51 billion in 2024, stood at US$14.73 billion in 2025 and is projected to advance at a resilient CAGR of 12.4% from 2025 to 2030, culminating in a forecasted valuation of US$26.40 billion by the end of the period. A biomarker (short for biological marker) is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response; this market includes consumables, services, and software used for biomarker-related research.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Infusion Pump Market by Product (Accessories (Dedicated, Non-dedicated), Devices (Insulin, Syringe, Volumetric, Enteral, PCA Pump)), Technology (Traditional, Specialty), Mode (Stationary, Portable), Application (Cancer, Diabetes) - Global Forecast to 2030
The global infusion pump market, valued at US$18.5 billion in 2024, stood at US$19.9 billion in 2025 and is projected to advance at a resilient CAGR of 7.4% from 2025 to 2030, culminating in a forecasted valuation of US$ 28.3 billion by the end of the period. The infusion pump market is expanding rapidly, driven by significant technological advancements in smart, interconnected, and automated systems that optimize the precision and safety of infusion therapy.
- Published: June 2025
- Price: $ 4950
- TOC Available:
-
Pain Management Devices Market by Type (Neurostimulation, Infusion Pump, Ablation), Application (Neuropathic, Musculoskeletal, Cancer pain), Mode of Purchase (Prescription, OTC), By End user (Hospital, Physiotherapy, Home care) - Global Forecast to 2029
The global pain management devices market, valued at US$3491.0 million in 2023, stood at US$3,768.6 million in 2024 and is projected to advance at a resilient CAGR of 9.1% from 2024 to 2029, culminating in a forecasted valuation of US$5,835.8 million by the end of the period. The increasing prevalence of chronic pain conditions, coupled with a growing number of surgical procedures, rising technological advancements, an expanding aging patient population, an established reimbursement framework promoting access to pain management devices, and emerging market opportunities are expected to drive market growth during the forecast period.
- Published: October 2024
- Price: $ 4950
- TOC Available:
-
Predictive Clinical Biomarkers Market by Product & Service (Consumable, Software), Technology (NGS, PCR), Disease (Cancer, Infectious), Application (Clinical Diagnostics)-Forecast to 2030
The predictive clinical biomarkers market, valued at US$7.84 billion in 2024, stood at US$8.49 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2025 to 2030, culminating in a forecasted valuation of US$14.69 billion by the end of the period. he market for predictive clinical biomarkers is growing rapidly as the healthcare industry shifts toward personalized and predictive medicine.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Prostate Health Market by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx), & Region (NA, Europe, APAC) - Global Forecast to 2026
The global prostate health market growth is primed to transition from USD 31.8 billion in 2021 to USD 48.9 billion by 2026, showcasing a strong CAGR of 9.0%. Growth in this market is primarily driven by the increasing prevalence of benign prostatic hyperplasia, increasing obesity, investments, funds, and grants for research in prostate health, an increase in the prevalence of prostate cancer, a surge in demand for hormone therapy drugs, emerging therapies for prostate cancer, and an increasing incidence of prostatitis.
- Published: December 2021
- Price: $ 4950
- TOC Available:
-
Veterinary Pain Management Market by Product (Drug (NSAIDs, Opioids), Route of Administration (Oral, Parenteral), Device (Laser)), Application (Joint Pain, Cancer), Animal (Companion and Livestock), End User (Hospital, Pharmacy) - Global Forecast to 2027
Veterinary pain management market growth is primed to transition from $1.8 billion in 2022 to $2.5 billion by 2027, showcasing a strong CAGR of 6.7%. Factors such as growth in companion animal adoption, the increasing number of veterinary practitioners and their rising income levels in developed economies, increasing consumption of meat & milk, the growing prevalence of animal disease causing pain and inflammation, and rising adoption of pet insurance with growing animal health expenditure are expected to drive the growth of this market.
- Published: September 2022
- Price: $ 4950
- TOC Available:
-
Theranostics Market by Product (Diagnostic imaging (PET, CT, MRI), Radiopharmaceuticals (Lu-177, Sm-153, Ra-223, I-131), Biomarker screening, Software), Application (Prostate Cancer, Bone metastasis), & Stakeholder Expectations - Global Forecast to 2028
The global theranostics market, valued at US$1.9 billion in 2022, stood at US$2.1 billion in 2023 and is projected to advance at a resilient CAGR of 15.5% from 2023 to 2028, culminating in a forecasted valuation of US$4.3 billion by the end of the period. Increasing establishment of hospitals, rising focus on targeted therapies, and introduction of novel theranostic approaches are expected to drive the market during the forecast period.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Gene Panel Market by Product & Service, Technique (Amplicon, Hybridization), Design (Predesign, Custom), Application (Cancer, Congenital Disease, Pharmacogenetics) & End User (Hospital, Research Center, Pharmaceutical Companies) - Global Forecasts to 2023
The global gene panel market is expected to reach USD 2.95 Billion by 2023, at a CAGR of 19.2%. The growth of this market is mainly driven by the increasing prevalence of chronic diseases, growing company initiatives, and rising adoption of gene panel owing to the benefits they offer. The gene panel market is fragmented, with the presence of several large as well as emerging players. Prominent players in the gene panels market include Illumina, Inc. (US), BGI (China), Agilent Technologies (US), Eurofins Scientific (US), QIAGEN (Germany), GENEWIZ, Inc. (US), Novogene Corporation (China), Personalis (US), Thermo Fisher Scientific (US), F. Hoffmann-La Roche AG (Switzerland), Integrated DNA Technologies (IDT) (US), GATC Biotech AG (GATC Biotech) (Germany), and ArcherDx (US). Players in this market are adopting various organic and inorganic strategies, such as product launches & upgradations, agreements, partnerships, joint ventures, collaborations, and acquisition to widen their product portfolios and expand their presence in the market.
- Published: May 2018
- Price: $ 4950
- TOC Available:
-
Whole Exome Sequencing Market by Product [Systems, Kits (Library Preparation, Target Enrichment)], Services (Sequencing), Technology (Sequencing by Synthesis), & by Application (Cancer, Monogenic disorders) - Global Forecast to 2018
This global whole exome sequencing market was valued at $326.6 million in 2013 and is expected to grow at a CAGR of 22.0% from 2013 to 2018, to reach $884.1 million by 2018. The market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). North America is expected to maintain its leadership in the market in the coming years. Growth in the North American market is likely to be driven by factors such as the increasing use of exome sequencing in rare disease research, increased government funding, and large number of sequencing-related conferences and annual meetings hosted by the U.S.
- Published: August 2014
- Price: $ 4950
- TOC Available:
Records 31 to 40 of 50
